RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Subscribe To Our Newsletter & Stay Updated
